"Czech Republic Pharmaceuticals & Healthcare Report Q3 2016" now available at Fast Market Research

From: Fast Market Research, Inc.
Published: Thu May 12 2016

The Czech Republic will continue to be one of the most attractive markets in the CEE region for pharmaceutical and healthcare investment. A strong economic outlook will be the driving factor behind growt h and with plans to further increase access to healthcare , pharmaceutical sales are expected to increase over the coming years.

Headline Expenditure Projections

Pharmaceuticals: CZK78.83bn (USD3.02bn) in 2015 to CZK81.15bn (USD3.28bn) in 2016; +3.0 % in local currency terms and +8.7 % in US dollar terms. Forecasts in line with last quarter.
Healthcare: CZK312.52bn (USD11.97bn) in 2015 to CZK325.75bn (USD13.17bn) in 2016; +4.2% in local currency terms and +10.1% in US dollar terms. Forecasts revised upwards from last quarter .

Full Report Details at
- http://www.fastmr.com/prod/1170508_czech_republic.aspx?afid=301

Risk/Reward Index

In Q3 2016, the Czech Republic Risk/Reward Index (RRI) score has been upgraded from the previous quarter to 65.5 out of 100. The Czech Republic is ranked as the most attractive market to innovative drugmakers in the Central and Eastern European (CEE) region within our RRI matrix. The Czech pharmaceutical market score is driven by high pharmaceutical expenditure per capita, an ageing population and a favourable urban-rural distribution, but dragged down by a challenging pricing and reimbursement environment.

Latest Updates

In April, representatives of the Ministries of Health for the Czech Republic, Hungary, Poland and Slovakia announced that they would consider cooperating in a joint purchasing agreement for rare disease medicines.

On April 6 2016, the Minister of Health announced a proposal to provide additional grants to doctors for medical equipment, nurses and salaries for practising in places where care is lacking. The new proposal is aimed at addressing the uneven distribution of healthcare provision around the country.

In March, the Czech Medical Council called on the government to introduce a health tax on alcohol and tobacco products.

BMI Economic View

Due partially to solid economic and employment growth rates, the Czech Republic's public finances will stay healthy in 2016 and 2017. Tax revenues will benefit from strong retail sales, while government borrowing costs will stay low amid record-low interest rates and the country's safe haven status.

BMI Political View

Relations between the Czech Republic and the EU will worsen over the coming quarters. We expect the Czech government to continue to oppose the EU's migrant reallocation system and re-introduce border controls in line with the other Central European states. Moreover, we believe further European integration will stay on hold in the years ahead.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Brazil Pharmaceuticals & Healthcare Report Q3 2016
- Bahrain Pharmaceuticals & Healthcare Report Q3 2016
- China Pharmaceuticals & Healthcare Report Q3 2016
- Italy Pharmaceuticals & Healthcare Report Q3 2016
- Belgium Pharmaceuticals & Healthcare Report Q3 2016

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »